Gender difference in disease severity and treatment outcomes among patients with rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) treated for one year with certolizumab pegol − analysis from the nationwide ATTRA registry of biological therapy

Czech version

Authors: J. Závada ^1,2; L. Nekvindová ^3,4
Authors‘ workplace: Revmatologický ústav, Praha ¹; Klinika revmatologie 1. LF UK, Praha ²; Institut biostatistiky a analýz, s. r. o., spin-off společnost Masarykovy univerzity, Brno ³; 1. LF UK, Praha ⁴
Published in: Čes. Revmatol., 29, 2021, No. 4, p. 191-196.
Category:

Overview

Introduction: The ATTRA registry captures more than 95% of patients with RA, AxSpA, or PSA treated with biologics in the Czech Republic (CZ).

Objectives: We aimed to investigate gender-related differences in baseline characteristics and treatment effectiveness among patients with RA, AxSpa, and PsA starting first-line therapy with certolizumab pegol (CZP) in CZ.

Methods: In this observational cohort study, the ATTRA registry provided prospectively collected data on RA, AxSpA, and PsA patients who initiated first-line therapy with CZP TT in 2012–6/2018. Treatment effectiveness was assessed at 12 months by a change in patient-reported outcomes (PROs) and the laboratory marker CRP. Differences in categorical and continuous data btw males and females were assessed using the Pearson χ2-test (of Fisher exact test, as appropriate), or Mann-Whitney test, respectively. This study was descriptive, and no statistical adjustments have been made.

Results: A total of 184 RA, 60 AxSpa, and 40 PsA patients were included. At the start of CZP treatment, men with RA and PsA had higher BMI and men with AxSpa had higher CRP than women; women with RA were more likely (current or former) smokers and had worse HAQ and EQ-5D scores, and women with AxSpa had higher fatigue scores than men. The improvement in patients’ quality of life assessed by the EQ-5D utility was higher in women with RA than in men after one year of CZP treatment. The fatigue score decreased more significantly in women with AxSpA than in men, while men with AxSpA showed a statistically more significant decrease in CRP than women.

Conclusions: CZP treatment had a similar, and in some aspects, even better effect on the quality of life in women with RA, AxSpA, and PsA after one year of follow-up compared to men.

Keywords:

registry – Quality of life – Psoriatic arthritis – biological therapy – certolizumab – rheumatoid arthritis – axial spondyloarthritis

Sources

Deeks ED. Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases. BioDrugs 2016; 30(6): 607–617.
https://www.ucb.com/stories-media/Press-Releases/article/ CIMZIA-certolizumab-pegol-label-change-marks-important- advance-for-European-women-of-childbearing-age-with-chronic-rheumatic-disease
Clowse MEB, Scheuerle AE, Chambers C, et al. Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database. Arthritis Rheumatol 2018; 70(9): 1399–1407.
Mariette X, Förger F, Abraham B, et al. Lack of placental transferof certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis 2018; 77(2): 228–233.
Clowse ME, Förger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis 2017; 76(11): 1890–1896.
Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum 2010; 62(6): 1576–1582. doi:10.1002/art.27425
Jawaheer D, Maranian P, Park G, Lahiff M, Amjadi SS, Paulus HE. Disease progression and treatment responses in a prospective DMARD-naive seropositive early rheumatoid arthritis cohort: does gender matter? J Rheumatol 2010; 37(12): 2475–2485. doi: 10.3899/jrheum.091432
Jawaheer D, Olsen J, Hetland ML. Sex differences in response to antitumor necrosis factor therapy in early and established rheumatoid arthritis: results from the DANBIO registry. J Rheumatol 2012; 39(1): 46–53. doi: 10.3899/jrheum.110548
Forslind K, Hafstrom I, Ahlmen M, Svensson B. Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis 2007; 66(1): 46–52. doi: 10.1136/ard.2006.056937
Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheu- matoid arthritis: results from the British society for rheumatology biologics register. Rheumatol (Oxford) 2006; 45(12): 1558–1565. doi: 10.1093/rheumatology/kel149
Jawaheer D, Messing S, Reed G, Ranganath VK, Kremer JM, Louie JS, Khanna D, Greenberg JD, Furst DE. Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2012; 64(12): 1811–1818. doi: 10.1002/acr.21762
Gran JT, Ostensen M, Husby G. A clinical comparison between males and females with ankylosing spondylitis. J Rheumatol 1985; 12(1): 126–129.
Kennedy LG,Will R,Calin A. Sex ratio in the spondyloarthropathies and its relationship to phenotypic expression, mode of in-heritance and age at onset. J Rheumatol 1993; 20(11): 1900–1904.

Will R, Edmunds L, Elswood J, Calin A. Is there sexual inequ- ality in ankylosing spondylitis? A study of 498 women and 1202 men. J Rheumatol 1990; 17(12): 1649–1652.
Gremese E, Bernardi S, Bonazza S, Nowik M, Peluso G, Massara A, et al. Body weight, gender and response to TNF-alpha blockers in axial spondyloarthritis. Rheumatology (Oxford) 2014; 53(5): 875–881.
Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991. J Rheumatol 2000; 27: 124–1250.
Gladman DD, Brubacher B, Buskila D, Langevitz P, Farewell VT. Psoriatic spondyloarthropathy in men and women: a clinical, radiographic, and HLA study. Clin Invest Med 1992; 15: 371–375.
Queiro R, Sarasqueta C, Torre JC, Tinture T, Lopez-Lagunas I. Comparative analysis of psoriatic spondyloarthropathy between men and women. Rheumatol Int 2001; 21: 66–68.

Labels

Dermatology & STDs Paediatric rheumatology Rheumatology

Gender difference in disease severity and treatment outcomes among patients with rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) starting treatment with targeted therapies in the Czech Republic − analysis from the nation-wide ATTRA registry of biological therapy

Validation of Czech versions of questionnaires assessing male sexual function and pelvic floor function

. IL-1 inhibition in the treatment of systemic juvenile arthritis and adult-onset Still's disease

ANCA associated vasculitis with skin ulcers of the cald, clinically manifested as pyoderma gangrenosum

KALENDÁŘ AKCÍ ČRS V ROCE 2022

Etiketa pro lékaře, zdravotníky a pomáhající profese

Article was published in

Czech Rheumatology

2021 Issue 4